Newly listed graphene technology company Sparc Technologies has moved quickly to launch a bio-medical project to develop non-invasive sensing devices for detection of disease via graphene-based breath sensors.
Last month Sparc debuted on the stock market with its shares immediately rising by more than 50 per cent.
The company sees potential global applications through identification of volatile organic compounds in the diagnosis and management of both animal and human diseases.
It envisages integration of graphene sensors with existing diagnostic tools and smart phones to enable real-time, portable disease detection.
The new division of the South Australian company, which has licenced graphene-based technologies from the University of Adelaide, will be led by medical device industry specialist Ben Yerbury.
Sparc executive chairman, Stephen hunt said: “We look forward to pioneering new technologies and applications for this revolutionary material and will seek to continue to be at the forefront of graphene.”
The university is a cornerstone shareholder in Sparc.
Subscribe to our free @AuManufacturing newsletter here.